Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.

Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, Wang A, Chu AA, Schaer GL, Stevens M, Wilensky RL, O'Neill WW; CONTRAST Investigators.

JAMA. 2003 Nov 5;290(17):2284-91.

PMID:
14600187
2.
3.

Preventing contrast-induced nephropathy with fenoldopam.

Hunter DW, Chamsuddin A, Bjarnason H, Kowalik K.

Tech Vasc Interv Radiol. 2001 Mar;4(1):53-6.

PMID:
11981789
4.

Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial.

Tumlin JA, Finkel KW, Murray PT, Samuels J, Cotsonis G, Shaw AD.

Am J Kidney Dis. 2005 Jul;46(1):26-34.

PMID:
15983954
5.

Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.

Stone GW, Tumlin JA, Madyoon H, Lepor NE, McCullough PA, Mathur VS, Murray PT, O'Neill WW.

Rev Cardiovasc Med. 2001;2 Suppl 1:S31-6.

PMID:
12439366
6.

Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.

Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK.

Catheter Cardiovasc Interv. 2002 Nov;57(3):279-83.

PMID:
12410497
7.

Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy.

Chamsuddin AA, Kowalik KJ, Bjarnason H, Dietz CA, Rosenberg MS, Gomes MD, McDermott CM, Hunter DW.

AJR Am J Roentgenol. 2002 Sep;179(3):591-6. Erratum in: AJR Am J Roentgenol 2002 Dec;179(6):1645.

PMID:
12185025
8.

Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study.

Huber W, Ilgmann K, Page M, Hennig M, Schweigart U, Jeschke B, Lutilsky L, Weiss W, Salmhofer H, Classen M.

Radiology. 2002 Jun;223(3):772-9.

PMID:
12034949
9.
10.

A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam.

Kini AS, Mitre CA, Kim M, Kamran M, Reich D, Sharma SK.

Catheter Cardiovasc Interv. 2002 Feb;55(2):169-73.

PMID:
11835641
11.

N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.

Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri P, Paolo Elia P, Golia B, Lepore S, Riviezzo G, Scarpato P, Librera M, Focaccio A, Ricciardelli B.

J Am Coll Cardiol. 2004 Aug 18;44(4):762-5.

12.

Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial.

Bove T, Zangrillo A, Guarracino F, Alvaro G, Persi B, Maglioni E, Galdieri N, Comis M, Caramelli F, Pasero DC, Pala G, Renzini M, Conte M, Paternoster G, Martinez B, Pinelli F, Frontini M, Zucchetti MC, Pappalardo F, Amantea B, Camata A, Pisano A, Verdecchia C, Dal Checco E, Cariello C, Faita L, Baldassarri R, Scandroglio AM, Saleh O, Lembo R, CalabrĂ² MG, Bellomo R, Landoni G.

JAMA. 2014 Dec 3;312(21):2244-53. doi: 10.1001/jama.2014.13573.

PMID:
25265449
13.

Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial.

Morelli A, Ricci Z, Bellomo R, Ronco C, Rocco M, Conti G, De Gaetano A, Picchini U, Orecchioni A, Portieri M, Coluzzi F, Porzi P, Serio P, Bruno A, Pietropaoli P.

Crit Care Med. 2005 Nov;33(11):2451-6.

PMID:
16276165
14.

A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients.

Brienza N, Malcangi V, Dalfino L, Trerotoli P, Guagliardi C, Bortone D, Faconda G, Ribezzi M, Ancona G, Bruno F, Fiore T.

Crit Care Med. 2006 Mar;34(3):707-14.

PMID:
16505657
15.

Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).

Ng TM, Shurmur SW, Silver M, Nissen LR, O'Leary EL, Rigmaiden RS, Cieciorka M, Porter LL, Ineck BA, Kline ME, Puumala SE.

Int J Cardiol. 2006 May 24;109(3):322-8. Epub 2005 Jul 22.

PMID:
16039733
16.

Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial--a randomized controlled study.

Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, Youn TJ, Chung WY, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS.

Am Heart J. 2008 Mar;155(3):499.e1-8. doi: 10.1016/j.ahj.2007.11.042. Epub 2008 Jan 30.

PMID:
18294484
17.

N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery.

Barr LF, Kolodner K.

Crit Care Med. 2008 May;36(5):1427-35. doi: 10.1097/CCM.0b013e31816f48ba.

PMID:
18434903
18.
19.
20.

Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.

Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE.

Am Heart J. 2003 Dec;146(6):E23.

PMID:
14661012
Items per page

Supplemental Content

Write to the Help Desk